Novo Nordisk AS
NVOHealthcare|Drug Manufacturers - General|Denmark
$49.48
+0.60 (+1.23%)
DCF (FCF)
$32.06
Tangible Book
$2.53
Graham Number
$14.22
Earnings Power
$19.73
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
44976.4,
45739.22,
48778.17,
53257.61,
56199.84
],
"ebit_estimate": [
19560.47,
18335.25,
20035.95,
22405.39,
22901.99
],
"ebitda_estimate": [
22117.81,
21643.55,
23252.77,
26219.39,
26770.11
],
"net_income_estimate": [
14665.04,
14323.46,
15647.44,
17993.14,
18648.91
],
"per_share_eps_estimate": [
3.52,
3.3,
3.71,
4.22,
4.45
],
"eps_nri_estimate": [
3.34,
3.29,
3.64,
4.19,
4.43
],
"dividend_estimate": [
1.82,
1.78,
1.93,
2.28,
2.35
],
"book_value_per_share_estimate": [
8.05,
9.14,
9.84,
10.4,
9.17
],
"pretax_income_estimate": [
19979.78,
18432.57,
19859.23,
22080.23,
22107.14
],
"operating_cash_flow_per_share_estimate": [
3.67,
3.87,
4.32,
4.95,
5.45
],
"roa_estimate": [
18.63,
16.25,
16.26,
19.4,
20.1
],
"roe_estimate": [
47.45,
40.16,
38.91,
42.7,
44.73
],
"gross_margin_estimate": [
80.71,
76.14,
78.87,
81.26,
80.65
],
"operating_cash_flow_estimate": [
16329.65,
17204.9,
19218.54,
22011.5,
24242.3
],
"pettm_estimate": [
14.04,
14.98,
13.33,
11.73,
11.11
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 18.59,
"future_roa_estimate_growth": -7.96,
"future_roe_estimate_growth": -15.62,
"future_gross_margin_estimate_growth": -1.42,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
10990.4,
11089.03,
11531.22,
11656.89,
11893.62,
11781.36,
12453.36
],
"ebit_estimate": [
4536.88,
4553.26,
4338.19,
null,
null,
null,
null
],
"ebitda_estimate": [
5247.17,
5218.15,
5141.98,
null,
null,
null,
null
],
"net_income_estimate": [
3547.17,
3583.73,
3368.29,
4023.59,
3858.34,
3725.93,
3448.12
],
"per_share_eps_estimate": [
0.8,
0.81,
0.78,
0.91,
0.88,
0.85,
0.78
],
"eps_nri_estimate": [
0.78,
0.75,
0.73,
0.85,
0.78,
0.77,
0.71
],
"dividend_estimate": [
0.57,
null,
1.22,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
9.05,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
4531.97,
4639.49,
4417.43,
null,
null,
null,
null
],
"operating_cash_flow_per_share_estimate": [
null,
4.68,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
21.3,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
50.9,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
81.38,
81.18,
81.05,
81,
80.8,
79.5,
79.3
],
"operating_cash_flow_estimate": [
null,
20828.46,
null,
null,
null,
null,
null
],
"pettm_estimate": [
15,
14.66,
14.51,
14.49,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 18.59,
"future_roa_estimate_growth": -7.96,
"future_roe_estimate_growth": -15.62,
"future_gross_margin_estimate_growth": -1.42,
"future_operating_cash_flow_per_share_estimate_growth": null
}